Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb 7;8(6):10264-10273.
doi: 10.18632/oncotarget.14382.

MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma

Jing Zhang  1 , Lei Guo  1 , Xiuyun Liu  1 , Wenbin Li  1 , Jianming Ying  1
Affiliations

MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma

Jing Zhang et al. Oncotarget. .

Abstract

This study was conducted to investigate the expression of MET in Chinese gastric adenocarcinoma cohort, the correlation between MET overexpression and clinical pathological features, HER2 expression and MET gene amplification. A total of 816 gastric adenocarcinoma patients were included and MET and HER2 immunohistochemical (IHC) staining were performed. IHC and dual-color silver in situ hybridization analysis were performed in the tissue microarrays, constructed from the 240 patients who were randomly selected. MET overexpression (IHC 3+) was observed in 6.0% (49/816) of the cohort. MET overexpression rate was higher in patients with poor prognostic factors, such as clinical stages III/IV (p =0.012) and pathologic stages T3/T4 (p =0.027). The HER2 overexpression (IHC 3+) rate was 8.8% (72/816) and MET overexpression rate was higher in HER2 positive patients (9.7%, 7/72). A high concordance rate (94.6%) between MET overexpression and gene amplification was demonstrated. Therefore, MET overexpression could serve as a prognostic biomarker and a potential therapeutic target for gastric cancer.

Keywords: MET gene amplification; MET overexpression; biomarker; gastric cancer; immunohistochemistry.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors have declared no conflicts of interest.

Figures

Figure 1
Figure 1. Representative microphotographs (A-H, ×200) of gastric cancer H&E staining A. and MET expression scored as 1+ B. 2+ C. 3+ D. in the membrane
And MET expression interpreted as 0 E. 1+ F. 2+ G. and 3+ H. in both membrane and cytoplasm of tumor cells. Representative microphotographs of MET DISH (I-L, ×400): disomy of normal gastric musco (IHC -) I. IHC 1+ J. IHC 2+ K. and gene amplification L. cases by DISH are shown.
Figure 2
Figure 2. Representative microphotographs of MET overexpression heterogeneity are showed (A&B, ×200)
Positive IHC staining of MET was seen in the right area but negative or weak staining in the left area in both picture A. and B.
See this image and copyright information in PMC

References

    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. - PubMed
    1. Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, Negri E, La Vecchia C, Lunet N. European journal of cancer. Vol. 50. Oxford, England: 1990. 2014. Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype; pp. 1330–1344. - PubMed
    1. Thiel A, Ristimaki A. Targeted therapy in gastric cancer. APMIS: acta pathologica, microbiologica, et immunologica Scandinavica. 2015;123:365–372. - PubMed
    1. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK, et al. Lancet. Vol. 376. London, England: 2010. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial; pp. 687–697. - PubMed
    1. Sheng WQ, Huang D, Ying JM, Lu N, Wu HM, Liu YH, Liu JP, Bu H, Zhou XY, Du X. HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. Ann Oncol. 2013;24:2360–2364. - PubMed

MeSH terms